Alterity Therapeutics is a development stage enterprise engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. Co. is developing therapies to treat neurodegenerative diseases. Co.'s primary drug candidate, ATH434 is for treatment of Parkinson's disease. Other applications for Co.'s main compounds include the treatment or amelioration of neurodegenerative disorders such as tauopathies, Motor Neuron disease, Creutzfeldt-Jakob disease, certain cancers, age-related macular degeneration, or antibiotic resistance.